Characteristics of long-term survivors with EGFR mutant (EGFRm) metastatic non-small cell lung cancer (mNSCLC)

• Published in: JTO clinical and research reports 2024, p.100669-100669
• Main Authors: Tompkins, William, MD, Grady, Connor B., MPH, Hwang, Wei-Ting, PhD, Chandrasekhara, Krishna, McCoach, Caroline, MD, Sun, Fangdi, MD, Liu, Geoffrey, MD, Patel, Devalben, MD, Nieva, Jorge, MD, Herrmann, Amanda, MD, Marrone, Kristen, MD, Lam, Vincent K., MD, Velcheti, Vamsi, MD, Liu, Stephen V., MD, Bravo Montenegro, Gabriela Liliana, MD, Patil, Tejas, MD, Weiss, Jared, MD, Miller, Kelsey Leigh, MD, Schwartzman, William, MD, Dowell, Jonathan E., MD, Shaverdashvili, Khvaramze, MD, Villaruz, Liza, MD, Cass, Amanda, PharmD, Iams, Wade, MD, Aisner, Dara, MD, PhD, Aggarwal, Charu, MD, Camidge, D. Ross, MD PhD, Marmarelis, Melina E., MD, Sun, Lova, MD
• Format: Article
• Language: English
• Subjects: Hematology, Oncology, and Palliative Medicine
• ISSN: 2666-3643; 2666-3643
• DOI: 10.1016/j.jtocrr.2024.100669

AbstractIntroductionCharacteristics of long-term survivors in EGFRm NSCLC are not fully understood. This retrospective analysis evaluated a multi-institution cohort of patients with EGFRm NSCLC treated in the pre-osimertinib era and sought to describe characteristics of long-term survivors. MethodsClinical characteristics and outcomes were abstracted from the electronic medical records of patients with EGFRm mNSCLC who started first-line therapy before 2015. Demographics and comutations were compared between ≥5 year survivors and